AR044004A1 - Formulacion farmaceutica por via oral para agentes antagonistas de bombas de protones - Google Patents

Formulacion farmaceutica por via oral para agentes antagonistas de bombas de protones

Info

Publication number
AR044004A1
AR044004A1 ARP040101186A ARP040101186A AR044004A1 AR 044004 A1 AR044004 A1 AR 044004A1 AR P040101186 A ARP040101186 A AR P040101186A AR P040101186 A ARP040101186 A AR P040101186A AR 044004 A1 AR044004 A1 AR 044004A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulation
oral route
antagonist agents
proton pumps
agents
Prior art date
Application number
ARP040101186A
Other languages
English (en)
Inventor
Dietrich Rango Dr
Haas Bernd-Michael Dr
Hartmut Ney
Hiltl Simone Dr
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33160619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044004(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10317023A external-priority patent/DE10317023A1/de
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of AR044004A1 publication Critical patent/AR044004A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de dosificación para agentes antagonistas de bombas de protones, soraprazano o una sal farmacológicamente aceptable y/o un hidrato del mismo, entre otros. El agente antagonista de bombas de protones es estabilizado en la forma de dosificación mediante uno o varios excipientes de carácter básico.
ARP040101186A 2003-04-11 2004-04-07 Formulacion farmaceutica por via oral para agentes antagonistas de bombas de protones AR044004A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008453 2003-04-11
DE10317023A DE10317023A1 (de) 2003-04-11 2003-04-11 Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten

Publications (1)

Publication Number Publication Date
AR044004A1 true AR044004A1 (es) 2005-08-24

Family

ID=33160619

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101186A AR044004A1 (es) 2003-04-11 2004-04-07 Formulacion farmaceutica por via oral para agentes antagonistas de bombas de protones

Country Status (19)

Country Link
US (1) US20060204568A1 (es)
EP (1) EP1615624A2 (es)
JP (1) JP2006522776A (es)
KR (1) KR20060002932A (es)
AR (1) AR044004A1 (es)
AU (1) AU2004228961A1 (es)
BR (1) BRPI0409175A (es)
CA (1) CA2526869A1 (es)
CL (1) CL2004000767A1 (es)
EA (1) EA200501565A1 (es)
IS (1) IS8107A (es)
MA (1) MA27772A1 (es)
MX (1) MXPA05010705A (es)
NO (1) NO20055207L (es)
PE (1) PE20050414A1 (es)
RS (1) RS20050756A (es)
TN (1) TNSN05233A1 (es)
TW (1) TW200503783A (es)
WO (1) WO2004089342A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US20080050428A1 (en) * 2004-10-05 2008-02-28 Altana Pharma Ag Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
PE20110591A1 (es) 2008-07-28 2011-09-15 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
TWI710379B (zh) 2015-07-30 2020-11-21 日商武田藥品工業股份有限公司 錠劑
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464372A (en) * 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8422461D0 (en) * 1984-09-05 1984-10-10 Wyeth John & Brother Ltd Pyridine derivatives
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4833149A (en) * 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6197783B1 (en) * 1997-03-24 2001-03-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyrido compounds
WO1998050019A1 (en) * 1997-05-09 1998-11-12 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
EA005377B1 (ru) * 1998-09-23 2005-02-24 Алтана Фарма Аг ТЕТРАГИДРОИМИДАЗО [1,2-h][1,7] НАФТИРИДИНОВЫЕ СОЕДИНЕНИЯ
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
AU775995B2 (en) * 1999-06-07 2004-08-19 Nycomed Gmbh Novel preparation and administration form comprising an acid-labile active compound
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
WO2001028559A1 (fr) * 1999-10-20 2001-04-26 Eisai Co., Ltd. Procede de stabilisation de composes benzimidazoles
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same

Also Published As

Publication number Publication date
TNSN05233A1 (en) 2007-06-11
US20060204568A1 (en) 2006-09-14
NO20055207L (no) 2005-11-04
IS8107A (is) 2005-10-31
WO2004089342A2 (en) 2004-10-21
KR20060002932A (ko) 2006-01-09
AU2004228961A1 (en) 2004-10-21
TW200503783A (en) 2005-02-01
BRPI0409175A (pt) 2006-04-11
EP1615624A2 (en) 2006-01-18
CA2526869A1 (en) 2004-10-21
EA200501565A1 (ru) 2006-06-30
WO2004089342A3 (en) 2005-03-10
MXPA05010705A (es) 2005-12-12
MA27772A1 (fr) 2006-02-01
RS20050756A (en) 2007-11-15
JP2006522776A (ja) 2006-10-05
PE20050414A1 (es) 2005-06-18
CL2004000767A1 (es) 2005-05-27

Similar Documents

Publication Publication Date Title
PE20040418A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
ECSP055726A (es) Composición farmacéutica estabilizada que contiene excipientes básicos
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
CO5611096A2 (es) Forma de dosificacion farmaceutica para administracion mucosal
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
AR059357A1 (es) Formulaciones farmaceuticas
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
SV2002000969A (es) Composicion parenteral reconstituible
AR034517A1 (es) Formulacion farmaceutica
AR044004A1 (es) Formulacion farmaceutica por via oral para agentes antagonistas de bombas de protones
AR062925A1 (es) Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
CR8172A (es) Saquinavir mesilato en forma de dosificacion farmaceutica oral
AR038858A1 (es) Combinacion
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal